Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 2/20 | 0.54 |
| ▸ | CSF1R | P07333 | 9/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5929647 | 0.86 | PDE4B (0.56) | PDE4BCSF1R | |
| SCHEMBL5929748 | 0.84 | CSF1R (0.78) | CSF1R | |
| SCHEMBL5929693 | 0.83 | CSF1R (0.69) | PDE4BCSF1R | |
| SCHEMBL5929864 | 0.83 | CSF1R (0.54) | PDE4BCSF1R | |
| SCHEMBL5929824 | 0.82 | CSF1R (0.68) | CSF1R | |
| SCHEMBL5929719 | 0.82 | CSF1R (0.68) | CSF1R | |
| SCHEMBL5929773 | 0.80 | CSF1R (0.70) | CSF1R | |
| SCHEMBL5929638 | 0.80 | CSF1R (0.67) | CSF1R | |
| SCHEMBL5929717 | 0.79 | CSF1R (0.69) | CSF1R | |
| SCHEMBL5929763 | 0.79 | PDE4B (0.56) | PDE4BCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | claimed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | claimed |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-08-03 | — | — | US | disclosed |
| US-7037925-B2 | 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2006-05-02 | — | — | US | disclosed |
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | ASTRAZENECA AB (SE) | 2004-12-09 | — | — | US | disclosed |
| EP-1387830-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | AstraZeneca AB (SE) | 2004-02-11 | — | — | EP | disclosed |
| WO-2002092571-A1 | NOVEL 4-ANILINOQUINOLINE-3-CARBOXAMIDES | ASTRAZENECA AB (SE) | 2002-11-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040248923-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | PDE4B 768/4885CSF1R 637/4885 |
| US-20060173034-A1 | Novel 4-anilinoquinoline-3-carboxamides | JAK3, JAK2, JAK1 | PDE4B 870/4885CSF1R 889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.